| Losartan, Hydrochlorithiazide |
20080150 |
TORES, Film coated tablet, 50 mg/12,5 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Stada Arzneimittel AG, Германия, Centrafarm Services, Netherlands, Stada Production Ireland, Ireland |
4.21 |
0.84 |
5.05 |
7% |
0.29 |
4.5 |
0.9 |
5.4 |
20% |
0.84 |
5.34 |
1.07 |
6.41 |
|
НСР-3139/26.03.2014 |
10.04.2014 |
10.04.2014 |
Неактивен |
2628 |
| Losartan, Hydrochlorithiazide |
20080150 |
TORES, Film coated tablet, 50 mg/12,5 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Stada Arzneimittel AG, Германия, Centrafarm Services, Netherlands, Stada Production Ireland, Ireland |
4.24 |
0.85 |
5.09 |
7% |
0.3 |
4.54 |
0.91 |
5.45 |
20% |
0.85 |
5.39 |
1.08 |
6.47 |
|
КЦРР-2179/06.02.2013 г |
25.02.2013 |
25.02.2013 |
Неактивен |
2628 |
| Losartan, Hydrochlorithiazide |
II-5942/ 07.10.2009 |
TORES, Film coated tablet, 50 mg/12,5 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Stada Production Ireland Ltd, Ирландия, Centrafarm Services B.V. Холандия Stada Arzneimittel AG, Германия |
4.83 |
0.97 |
5.8 |
7% |
0.34 |
5.17 |
1.03 |
6.2 |
20% |
0.97 |
6.14 |
1.23 |
7.37 |
|
КЦРР-1184/13.08.2012 |
14.09.2012 |
14.09.2012 |
Неактивен |
2628 |
| Losartan, Hydrochlorithiazide |
II-5942/ 07.10.2009 |
TORES, Film coated tablet, 50 mg/12,5 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Stada Production Ireland Ltd, Ирландия, Centrafarm Services B.V. Холандия Stada Arzneimittel AG, Германия |
5.32 |
1.06 |
6.38 |
7% |
0.37 |
5.69 |
1.14 |
6.83 |
20% |
1.06 |
6.75 |
1.35 |
8.1 |
|
КЦРР-652/19.05.2012 |
05.06.2012 |
05.06.2012 |
Неактивен |
2628 |
| Losartan, Hydrochlorithiazide |
5942/07.10.2009 |
TORES, Film coated tablet, 50 mg/12,5 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Stada Production Ireland Ltd, Ирландия, Centrafarm Services B.V. Холандия Stada Arzneimittel AG, Германия |
6.83 |
1.37 |
8.2 |
9% |
0.61 |
7.44 |
1.49 |
8.93 |
22% |
1.5 |
8.94 |
1.79 |
10.73 |
|
КЦ-1342/01.02.2010 |
22.02.2010 |
22.02.2010 |
Неактивен |
2628 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, cconcentrate and solvent for solution for infusion, 30, mg, Pack: concentrate: 1.2 ml; diluent: 1.8 ml 1 vial + 1 vial |
Pfizer Limited, Обединено Кралство |
Wyeth Lederle S.p.A., Италия |
1379.74 |
275.95 |
1655.69 |
4% |
10 |
1389.74 |
277.95 |
1667.69 |
16% |
25 |
1414.74 |
282.95 |
1697.69 |
|
НСР-5031/17.11.2014 |
01.12.2014 |
01.12.2014 |
Неактивен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, cconcentrate and solvent for solution for infusion, 30, mg, Pack: concentrate: 1.2 ml; diluent: 1.8 ml 1 vial + 1 vial |
Pfizer Limited, Обединено Кралство |
Wyeth Lederle S.p.A., Италия |
1602.78 |
320.56 |
1923.34 |
4% |
10 |
1612.78 |
322.56 |
1935.34 |
16% |
25 |
1637.78 |
327.56 |
1965.34 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-259/18.12.2013 |
НСР-67/07.06.2013 |
16.03.2014 |
16.03.2014 |
Неактивен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, cconcentrate and solvent for solution for infusion, 30, mg, Pack: concentrate: 1.2 ml; diluent: 1.8 ml 1 vial + 1 vial |
Pfizer Limited, Обединено Кралство |
Wyeth Lederle S.p.A., Италия |
1715.11 |
343.02 |
2058.13 |
4% |
10 |
1725.11 |
345.02 |
2070.13 |
16% |
25 |
1750.11 |
350.02 |
2100.13 |
промяна на обстоятелства решение КЦPP-1463/02.10.2012 |
КЦ-180/04.08.2008; 24.10.2012. |
28.08.2008 |
28.08.2008 |
Неактивен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, Concentrate and diluent for solution for infusion, 30 mg (concentrate: 1.2 ml; diluent: 1.8 ), -, Pack: 1 vial + 1 vial |
Pfizer Europe MA EEIG, Белгия |
Wyeth Lederle S.p.A., Италия |
1314.55 |
262.91 |
1577.46 |
4% |
10 |
1324.55 |
264.91 |
1589.46 |
16% |
25 |
1349.55 |
269.91 |
1619.46 |
Промяна на обстоятелствата НСР-17315/22.11.2018 |
НСР-8330/26.02.2016; НСР-11064/01.12.2016; НСР-15115/26.02.2018 Предварително изпълнение; НСР-19971/11.10.2019-Предварително изпълнение |
11.10.2019 |
02.11.2019 |
Активен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, Concentrate and diluent for solution for infusion, 30 mg (concentrate: 1.2 ml; diluent: 1.8 ), -, Pack: 1 vial + 1 vial |
Pfizer Europe MA EEIG, Белгия |
Wyeth Lederle S.p.A., Италия |
1354.9 |
270.98 |
1625.88 |
4% |
10 |
1364.9 |
272.98 |
1637.88 |
16% |
25 |
1389.9 |
277.98 |
1667.88 |
Промяна на обстоятелствата НСР-17315/22.11.2018 |
НСР-8330/26.02.2016; НСР-11064/01.12.2016; НСР-15115/26.02.2018 Предварително изпълнение |
26.02.2018 |
02.01.2019 |
Неактивен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, Concentrate and diluent for solution for infusion, 30 mg (concentrate: 1.2 ml; diluent: 1.8 ), -, Pack: 1 vial + 1 vial |
Pfizer Europe MA EEIG, Белгия |
Wyeth Lederle S.p.A., Италия |
1354.9 |
270.98 |
1625.88 |
4% |
10 |
1364.9 |
272.98 |
1637.88 |
16% |
25 |
1389.9 |
277.98 |
1667.88 |
Промяна на обстоятелствата НСР-17315/22.11.2018 |
НСР-8330/26.02.2016; НСР-11064/01.12.2016; НСР-15115/26.02.2018 Предварително изпълнение |
26.02.2018 |
02.01.2019 |
Неактивен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, Concentrate and diluent for solution for infusion, 30 mg (concentrate: 1.2 ml; diluent: 1.8 ), -, Pack: 1 vial + 1 vial |
Pfizer Limited, Обединено Кралство |
Wyeth Lederle S.p.A., Италия |
1354.9 |
270.98 |
1625.88 |
4% |
10 |
1364.9 |
272.98 |
1637.88 |
16% |
25 |
1389.9 |
277.98 |
1667.88 |
|
НСР-8330/26.02.2016; НСР-11064/01.12.2016; НСР-15115/26.02.2018 Предварително изпълнение |
26.02.2018 |
02.03.2018 |
Неактивен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, Concentrate and diluent for solution for infusion, 30 mg (concentrate: 1.2 ml; diluent: 1.8 ), -, Pack: 1 vial + 1 vial |
Pfizer Limited, Обединено Кралство |
Wyeth Lederle S.p.A., Италия |
1365.91 |
273.18 |
1639.09 |
4% |
10 |
1375.91 |
275.18 |
1651.09 |
16% |
25 |
1400.91 |
280.18 |
1681.09 |
|
НСР-8330/26.02.2016; НСР-11064/01.12.2016 |
17.12.2016 |
02.01.2017 |
Неактивен |
3375 |
| Temsirolimus |
EU/1/07/424/001 |
TORISEL, Concentrate and diluent for solution for infusion, 30 mg (concentrate: 1.2 ml; diluent: 1.8 ), -, Pack: 1 vial + 1 vial |
Pfizer Limited, Обединено Кралство |
Wyeth Lederle S.p.A., Италия |
1375.1 |
275.02 |
1650.12 |
4% |
10 |
1385.1 |
277.02 |
1662.12 |
16% |
25 |
1410.1 |
282.02 |
1692.12 |
|
НСР-8330/26.02.2016 |
16.03.2016 |
16.03.2016 |
Неактивен |
3375 |
| Torasemide |
20120246 |
Torsit SR, Prolonged release tablet, 10, mg, Pack: 30 |
Ferrer International S.A.,, Испания |
Ferrer internacional S.A., Spain |
6.63 |
1.33 |
7.96 |
7% |
0.46 |
7.09 |
1.42 |
8.51 |
20% |
1.33 |
8.42 |
1.68 |
10.1 |
Протокол №242/14.09.2017; Промяна на обстоятелства НСР-14167/13.10.2017; НСР-19358/26.07.2019 |
НСР-899/09.08.2013 |
18.09.2013 |
02.09.2019 |
Активен |
2096 |
| Torasemide |
20120246 |
Torsit SR, Prolonged release tablet, 10, mg, Pack: 30 |
Унифарма ООД, България |
Ferrer internacional S.A., Spain |
6.63 |
1.33 |
7.96 |
7% |
0.46 |
7.09 |
1.42 |
8.51 |
20% |
1.33 |
8.42 |
1.68 |
10.1 |
Протокол №242/14.09.2017; Промяна на обстоятелства НСР-14167/13.10.2017 |
НСР-899/09.08.2013 |
18.09.2013 |
02.11.2017 |
Неактивен |
2096 |
| Torasemide |
20120245 |
Torsit SR, Prolonged release tablet, 5, mg, Pack: 30 |
Ferrer International S.A.,, Испания |
Ferrer internacional S.A., Spain |
3.32 |
0.66 |
3.98 |
7% |
0.23 |
3.55 |
0.71 |
4.26 |
20% |
0.66 |
4.21 |
0.84 |
5.05 |
Протокол №242/14.09.2017; Промяна на обстоятелства НСР-14166/13.10.2017; НСР-19357/26.07.2019 |
НСР-4930/22.10.2014 |
06.11.2014 |
02.09.2019 |
Активен |
3317 |
| Torasemide |
20120245 |
Torsit SR, Prolonged release tablet, 5, mg, Pack: 30 |
Унифарма ООД, България |
Ferrer internacional S.A., Spain |
3.32 |
0.66 |
3.98 |
7% |
0.23 |
3.55 |
0.71 |
4.26 |
20% |
0.66 |
4.21 |
0.84 |
5.05 |
Протокол №242/14.09.2017; Промяна на обстоятелства НСР-14166/13.10.2017 |
НСР-4930/22.10.2014 |
06.11.2014 |
02.11.2017 |
Неактивен |
3317 |
| Torasemide |
20120245 |
Torsit SR, Prolonged release tablet, 5, mg, Pack: 30 |
Унифарма ООД, България |
Ferrer internacional S.A., Spain |
3.32 |
0.66 |
3.98 |
7% |
0.23 |
3.55 |
0.71 |
4.26 |
20% |
0.66 |
4.21 |
0.84 |
5.05 |
Протокол №242/14.09.2017; Промяна на обстоятелства НСР-14166/13.10.2017 |
НСР-4930/22.10.2014 |
06.11.2014 |
02.11.2017 |
Неактивен |
3317 |
| Torasemide |
20120245 |
Torsit SR, Prolonged release tablet, 5, mg, Pack: 30 |
Унифарма ЕООД, България |
Ferrer internacional S.A., Spain |
3.32 |
0.66 |
3.98 |
7% |
0.23 |
3.55 |
0.71 |
4.26 |
20% |
0.66 |
4.21 |
0.84 |
5.05 |
Протокол №242/14.09.2017 |
НСР-4930/22.10.2014 |
06.11.2014 |
02.10.2017 |
Неактивен |
3317 |
| Torasemide |
20120246 |
Torsit SR, Prolonged release tablet, 10, mg, Pack: 30 |
Унифарма ЕООД, България |
Ferrer internacional S.A., Spain |
6.63 |
1.33 |
7.96 |
7% |
0.46 |
7.09 |
1.42 |
8.51 |
20% |
1.33 |
8.42 |
1.68 |
10.1 |
Протокол №242/14.09.2017 |
НСР-899/09.08.2013 |
18.09.2013 |
02.10.2017 |
Неактивен |
2096 |
| Torasemide |
20120246 |
Torsit SR, Prolonged release tablet, 5, mg, Pack: 30 |
Унифарма ЕООД, България |
Ferrer internacional S.A., Spain |
3.32 |
0.66 |
3.98 |
7% |
0.23 |
3.55 |
0.71 |
4.26 |
20% |
0.66 |
4.21 |
0.84 |
5.05 |
|
НСР-4930/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3317 |
| Torasemide |
20120246/14.05.2012 |
Torsit SR, Prolonged release tablet, 10, mg, Pack: 30 |
Унифарма ЕООД, България |
Ferrer internacional S.A., Spain |
6.63 |
1.33 |
7.96 |
7% |
0.46 |
7.09 |
1.42 |
8.51 |
20% |
1.33 |
8.42 |
1.68 |
10.1 |
|
НСР-899/09.08.2013 |
18.09.2013 |
18.09.2013 |
Неактивен |
2096 |
| Torasemide |
20120246 |
Torsit SR, Prolonged release tablet, 5, mg, Pack: 30 |
Унифарма ЕООД, България |
Ferrer internacional S.A., Spain |
3.32 |
0.66 |
3.98 |
7% |
0.23 |
3.55 |
0.71 |
4.26 |
20% |
0.66 |
4.21 |
0.84 |
5.05 |
|
НСР-4930/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3317 |
| Torasemide |
20120246 |
Torsit SR, Prolonged release tablet, 5, mg, Pack: 30 |
Фармаконс АД, България |
Ferrer internacional S.A., Spain |
3.32 |
0.66 |
3.98 |
7% |
0.23 |
3.55 |
0.71 |
4.26 |
20% |
0.66 |
4.21 |
0.84 |
5.05 |
|
НСР-4930/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3317 |